Evrópusambandið - spænska - EMA (European Medicines Agency)

novartis europharm limited - ceritinib - carcinoma, pulmón no microcítico - agentes antineoplásicos - zykadia está indicado para el tratamiento de pacientes adultos con linfoma anaplásico kinasa (alk) positivo avanzado cáncer de pulmón de células no pequeñas (cpcnp) previamente tratado con crizotinib.

Evrópusambandið - spænska - EMA (European Medicines Agency)

roche registration gmbh - erlotinib - carcinoma, non-small-cell lung; pancreatic neoplasms - agentes antineoplásicos - de células no pequeñas de cáncer de pulmón no microcítico (cpnm)tarceva también está indicado para el interruptor de tratamiento de mantenimiento en pacientes con localmente avanzado o metastásico de células no pequeñas de cáncer de pulmón con mutaciones activadoras de egfr y estable de la enfermedad después de la quimioterapia de primera línea. tarceva también está indicado para el tratamiento de pacientes con localmente avanzado o metastásico de células no pequeñas de cáncer de pulmón después del fracaso de al menos un régimen de quimioterapia antes de la. en los pacientes con tumores sin mutaciones activadoras de egfr, tarceva está indicado cuando otras opciones de tratamiento no se consideran adecuadas. cuando la prescripción de tarceva, los factores asociados con la supervivencia prolongada debe ser tomado en cuenta. ningún beneficio de supervivencia o de otros clínicamente relevantes efectos del tratamiento se han demostrado en pacientes con factor de crecimiento epidérmico (egfr)-ihc negativo de tumores. páncreas cancertarceva en combinación con gemcitabina está indicada para el tratamiento de pacientes con cáncer de páncreas con metástasis. cuando la prescripción de tarceva, los factores asociados con la supervivencia prolongada debe ser tomado en cuenta.

Evrópusambandið - spænska - EMA (European Medicines Agency)

astrazeneca ab - durvalumab - carcinoma, pulmón no microcítico - agentes antineoplásicos - non-small cell lung cancer (nsclc)imfinzi as monotherapy is indicated for the treatment of locally advanced, unresectable non small cell lung cancer (nsclc) in adults whose tumours express pd-l1 on ≥ 1% of tumour cells and whose disease has not progressed following platinum based chemoradiation therapy (see section 5. imfinzi in combination with tremelimumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic nsclc with no sensitising egfr mutations or alk positive mutations. small cell lung cancer (sclc)imfinzi in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adults with extensive-stage small cell lung cancer (es-sclc). biliary tract cancer (btc)imfinzi in combination with gemcitabine and cisplatin is indicated for the first line treatment of adults with unresectable or metastatic biliary tract cancer (btc). hepatocellular carcinoma (hcc)imfinzi in combination with tremelimumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc).

Evrópusambandið - spænska - EMA (European Medicines Agency)

regeneron ireland designated activity company (dac) - cemiplimab - carcinoma, célula escamosa - agentes antineoplásicos - cutaneous squamous cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mcscc or lacscc) who are not candidates for curative surgery or curative radiation. basal cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic basal cell carcinoma (labcc or mbcc) who have progressed on or are intolerant to a hedgehog pathway inhibitor (hhi). non-small cell lung cancerlibtayo as monotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (nsclc) expressing pd-l1 (in ≥ 50% tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. libtayo in combination with platinum‐based chemotherapy is indicated for the first‐line treatment of adult patients with nsclc expressing pd-l1 (in ≥ 1% of tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. cervical cancerlibtayo as monotherapy is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy.

Evrópusambandið - spænska - EMA (European Medicines Agency)

pfizer europe ma eeig - lorlatinib - carcinoma, pulmón no microcítico - antineoplastic agents, protein kinase inhibitors - lorviqua as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. lorviqua as monotherapy is indicated for the treatment of adult patients with alk‑positive advanced nsclc whose disease has progressed after:alectinib or ceritinib as the first alk tyrosine kinase inhibitor (tki) therapy; orcrizotinib and at least one other alk tki.

Evrópusambandið - spænska - EMA (European Medicines Agency)

pfizer europe ma eeig - dacomitinib monohidrato - carcinoma, pulmón no microcítico - agentes antineoplásicos - vizimpro, como monoterapia, está indicado para el tratamiento de primera línea de pacientes adultos con localmente avanzado o metastásico, no cáncer de pulmón microcítico (cpnm) con factor de crecimiento epidérmico (egfr) la activación de mutaciones.

Perú - spænska - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

intihuatana pharmaceutical s.a.c. - droguerÍa - polvo para suspension oral - por sobre 20.00 g - - todo el resto de los productos terapÉuticos

Gvatemala - spænska - Gobierno de Guatemala, Ministerio de Salud Pública y Asistencia Social (Departamento de Regulación y Control de Productos Farmacéuticos y Afines)

biologische heilmittel heel gmbh - solución inyectable

Síle - spænska - ISPC (Instituto de Salud Pública de Chile)

productos farmacÉuticos heel chile ltda. - acidum phosphoricum d10 22 mg/2.2 ml; aconitum napellus d6 22 mg/2.2 ml; aesculus hippocastanum d4 22 mg/2.2 ml; ambra grisea d10 22 mg/2.2 ml; anamirta cocculus d4 22 mg/2.2 ml; arnica montana d28 22 mg/2.2 ml; cerebrum suis d8 22 mg/2.2 ml; cinchona pubescens d4 22 mg/2.2 ml; conium maculatum d4 22 mg/2.2 ml; embryo suis d10 22 mg/2.2 ml; gelsemium sempervirens d4 22 mg/2.2 ml; hepar suis d10 22 mg/2.2 ml; kalium phosphoricum d6 22 mg/2.2 ml; magnesium phosphoricum d10 22 mg/2.2 ml; manganum phosphoricum d8 22 mg/2.2 ml; ruta graveolens d4 22 mg/2.2 ml; selenium d10 22 mg/2.2 ml; semecarpus anacardium d6 22 mg/2.2 ml; strychnos ignatii d8 22 mg/2.2 ml; sulfur d10 22 mg/2.2 ml; thuja occidentalis d6 22 mg/2.2 ml - medicamento homeopatico util como coadyuvante en enfermedades del sistema nervioso central. se autoriza vía de administración intravenosa (i.v.)

Evrópusambandið - spænska - EMA (European Medicines Agency)

roche registration gmbh  - pralsetinib - carcinoma, pulmón no microcítico - agentes antineoplásicos - gavreto is indicated as monotherapy for the treatment of adult patients with rearranged during transfection (ret) fusion-positive advanced non-small cell lung cancer (nsclc) not previously treated with a ret inhibitor.